FindTrial
Sign In

[68Ga]Ga-NeoB

DRUG5 trials

Sponsors

Novartis Pharmaceuticals, St Vincent's Hospital, Sydney

Conditions

Breast CancerMetastatic Neuroendocrine Prostate CancerNewly Diagnosed and Recurrent Glioblastoma

Phase 1

Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma
Active, not recruitingNCT05739942
Novartis PharmaceuticalsNewly Diagnosed and Recurrent Glioblastoma
Start: 2024-05-15End: 2032-07-01Updated: 2026-02-03
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
RecruitingNCT05870579
Novartis PharmaceuticalsBreast Cancer
Start: 2023-11-13End: 2032-01-26Target: 48Updated: 2025-08-21
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
RecruitingNCT06247995
Novartis PharmaceuticalsBreast Cancer
Start: 2024-08-14End: 2031-09-09Target: 58Updated: 2025-11-06
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
Active, not recruitingNCT06379217
Novartis PharmaceuticalsMetastatic Neuroendocrine Prostate Cancer
Start: 2024-07-29End: 2026-08-27Updated: 2026-03-11

Phase 2

Pilot Trial to Assess 68Ga Bombesin PET/CT (NeoB) Imaging for Staging of Breast Cancer
NCT05889728
St Vincent's Hospital, SydneyBreast Cancer
Start: 2023-02-20End: 2025-02-23Target: 20Updated: 2023-06-05

Related Papers

TIP-22. Trial in progress: A Phase Ib dose-finding study and evaluation of [177Lu]Lu-NeoB plus radiotherapy and temozolomide for newly diagnosed glioblastoma and as a single agent for recurrent glioblastoma
Neuro-Oncology2025-11-01
Abstract P3-10-21: Phase Ib dose-finding study of [177Lu]Lu-NeoB + ribociclib + fulvestrant in patients w/ ER+/HER2- advanced breast cancer (ABC) w/ GRPR expression w/ early relapse from (neo)adjuvant endocrine therapy (ET) or progression on ET + CDK4/6i for ABC
Clinical Cancer Research2025-06-13
Abstract P3-10-17: Phase I/II study of the novel radioligand therapy [177Lu]Lu-NeoB plus capecitabine in patients w/ ER+/HER2- advanced breast cancer (ABC) w/GRPR expression after progression on prior endocrine therapy (ET) plus a CDK4/6 inhibitor (CDK4/6i) for ABC
Clinical Cancer Research2025-06-13